SQZ Biotechnologies (SQZB) Stock Price, News & Analysis

Company Overview

SQZ Biotechnologies Co. was a biotechnology company that developed cell therapies using its proprietary Cell Squeeze platform. The technology was designed to deliver biological materials, including proteins, nucleic acids and other therapeutic agents, directly into cells without relying on conventional viral vectors.

The company focused primarily on oncology and immune-mediated diseases. Its research programs included engineered immune-cell therapies intended to recognize and attack cancer, as well as approaches designed to enhance the function of immune cells. SQZ Biotechnologies also pursued partnerships and collaborations to apply its platform to additional therapeutic areas.

Founded in 2013 and headquartered in Woburn, Massachusetts, the company advanced several investigational programs into clinical development. Armon Sharei, one of the company’s co-founders, served as its chief executive officer during much of its corporate and clinical development. SQZ Biotechnologies later announced plans to wind down operations and pursue liquidation, and its securities subsequently became quoted on the over-the-counter market under the symbol SQZB.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.02
• 52-Week Range: $0.02 to $0.05
• Volume: 148 shs
• Average Volume: 59,439 shs
• Market Capitalization: $707.76 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SQZ Biotechnologies Stock Analysis - MarketRank™

SQZ Biotechnologies scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for SQZ Biotechnologies.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of SQZ Biotechnologies is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SQZ Biotechnologies is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of SQZ Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

SQZ Biotechnologies has a short interest ratio ("days to cover") of 1.34, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SQZ Biotechnologies has recently decreased by 65.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SQZ Biotechnologies does not currently pay a dividend.

Dividend Growth

SQZ Biotechnologies does not have a long track record of dividend growth.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.19

News Sentiment

SQZ Biotechnologies has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for SQZ Biotechnologies this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SQZ Biotechnologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.00% of the stock of SQZ Biotechnologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

12.41% of the stock of SQZ Biotechnologies is held by institutions.

Company Calendar

• Today: 10/13/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:SQZB
• CIK: 1604477
• Web: www.sqzbiotech.com
• Phone: 617-758-8672
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 29,490,000
• Free Float: 24,772,000
• Market Cap: $707.76 thousand
• Optionable: N/A
• Beta: 0.38